Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert Answers

This engaging symposium focussed on the rationale and current evidence supporting the role for poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with cancer. The meeting opened with an overview of DNA repair and the biological basis for targeting this process in oncology, d...

Full description

Bibliographic Details
Main Authors: Tristin Abair, Hilary Calvert, Nicoletta Colombo, Eric Pujade-Lauraine, Andrew Tutt, Eric Van Cutsem
Format: Article
Language:English
Published: European Medical Journal 2015-11-01
Series:European Medical Journal Oncology
Subjects:
ECC
Online Access:http://emjreviews.com/wp-content/uploads/Incorporating-PARP-Inhibition-in-Cancer-Therapy-Key-Questions-Expert-Answers.pdf
id doaj-2dbe38692ac74d62837e561cb1b184f3
record_format Article
spelling doaj-2dbe38692ac74d62837e561cb1b184f32020-11-24T21:23:05ZengEuropean Medical JournalEuropean Medical Journal Oncology2054-619X2015-11-01324958Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert AnswersTristin Abair0Hilary Calvert1Nicoletta Colombo2Eric Pujade-Lauraine3Andrew Tutt4Eric Van Cutsem5prIME Oncology, Atlanta, Georgia, USA University College London, London, UK European Institute of Oncology, Milan, Italy Centre Hospitalier Universitaire Hôtel-Dieu, Paris, France King’s College London School of Medicine, London, UK University Hospital Gasthuisberg, Leuven, BelgiumThis engaging symposium focussed on the rationale and current evidence supporting the role for poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with cancer. The meeting opened with an overview of DNA repair and the biological basis for targeting this process in oncology, delivered by Prof Calvert. This was followed by a discussion from Prof Pujade-Lauraine that focussed on patient selection for PARP inhibition and the role for these agents in BRCA -mutated and BRCA -like cancers. Next, Prof Colombo presented a clinical scenario of BRCA -associated ovarian cancer and examined optimal treatment options in the first-line setting and for progressive disease. She also highlighted current clinical data and ongoing trials evaluating PARP inhibition in advanced ovarian cancer. Prof Tutt then discussed the potential role for PARP inhibitors in patients with breast cancer, focussing on a clinical scenario of triple-negative disease and emphasising current and investigational treatment options. Lastly, Prof Van Cutsem described emerging data and ongoing clinical studies evaluating PARP inhibition in the treatment of patients with pancreatic and gastric cancers, and how this could impact future clinical practice. The programme also included a PARP quiz, in which participants were polled at the beginning and conclusion of the symposium to examine their knowledge and practice patterns regarding the use of PARP inhibitors in oncology. The key highlights from these presentations and the PARP quiz are summarised herein.http://emjreviews.com/wp-content/uploads/Incorporating-PARP-Inhibition-in-Cancer-Therapy-Key-Questions-Expert-Answers.pdfECCEuropean Cancer Congress
collection DOAJ
language English
format Article
sources DOAJ
author Tristin Abair
Hilary Calvert
Nicoletta Colombo
Eric Pujade-Lauraine
Andrew Tutt
Eric Van Cutsem
spellingShingle Tristin Abair
Hilary Calvert
Nicoletta Colombo
Eric Pujade-Lauraine
Andrew Tutt
Eric Van Cutsem
Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert Answers
European Medical Journal Oncology
ECC
European Cancer Congress
author_facet Tristin Abair
Hilary Calvert
Nicoletta Colombo
Eric Pujade-Lauraine
Andrew Tutt
Eric Van Cutsem
author_sort Tristin Abair
title Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert Answers
title_short Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert Answers
title_full Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert Answers
title_fullStr Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert Answers
title_full_unstemmed Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert Answers
title_sort incorporating parp inhibition in cancer therapy: key questions, expert answers
publisher European Medical Journal
series European Medical Journal Oncology
issn 2054-619X
publishDate 2015-11-01
description This engaging symposium focussed on the rationale and current evidence supporting the role for poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with cancer. The meeting opened with an overview of DNA repair and the biological basis for targeting this process in oncology, delivered by Prof Calvert. This was followed by a discussion from Prof Pujade-Lauraine that focussed on patient selection for PARP inhibition and the role for these agents in BRCA -mutated and BRCA -like cancers. Next, Prof Colombo presented a clinical scenario of BRCA -associated ovarian cancer and examined optimal treatment options in the first-line setting and for progressive disease. She also highlighted current clinical data and ongoing trials evaluating PARP inhibition in advanced ovarian cancer. Prof Tutt then discussed the potential role for PARP inhibitors in patients with breast cancer, focussing on a clinical scenario of triple-negative disease and emphasising current and investigational treatment options. Lastly, Prof Van Cutsem described emerging data and ongoing clinical studies evaluating PARP inhibition in the treatment of patients with pancreatic and gastric cancers, and how this could impact future clinical practice. The programme also included a PARP quiz, in which participants were polled at the beginning and conclusion of the symposium to examine their knowledge and practice patterns regarding the use of PARP inhibitors in oncology. The key highlights from these presentations and the PARP quiz are summarised herein.
topic ECC
European Cancer Congress
url http://emjreviews.com/wp-content/uploads/Incorporating-PARP-Inhibition-in-Cancer-Therapy-Key-Questions-Expert-Answers.pdf
work_keys_str_mv AT tristinabair incorporatingparpinhibitionincancertherapykeyquestionsexpertanswers
AT hilarycalvert incorporatingparpinhibitionincancertherapykeyquestionsexpertanswers
AT nicolettacolombo incorporatingparpinhibitionincancertherapykeyquestionsexpertanswers
AT ericpujadelauraine incorporatingparpinhibitionincancertherapykeyquestionsexpertanswers
AT andrewtutt incorporatingparpinhibitionincancertherapykeyquestionsexpertanswers
AT ericvancutsem incorporatingparpinhibitionincancertherapykeyquestionsexpertanswers
_version_ 1725993502658002944